Publications
Publications
  • September 2005 (Revised June 2006)
  • Case
  • HBS Case Collection

WuXi PharmaTech

By: Richard G. Hamermesh and Simin Zhou
  • Format:Print
  • | Pages:25
ShareBar

Abstract

WuXi Pharmatech has gone from zero to $21 million in sales in three years. The company must decide its growth strategy and how best to finance and organize for rapid growth.

Keywords

Growth Management; Capital Markets; Problems and Challenges; Pharmaceutical Industry; China

Citation

Hamermesh, Richard G., and Simin Zhou. "WuXi PharmaTech." Harvard Business School Case 806-003, September 2005. (Revised June 2006.)

More from the Authors